DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use

Phase 3

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Adalimumab

First Posted Date: 2008-10-20

Last Posted Date: 2016-01-26

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 32

Registration Number: NCT00775437

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

Phase 3

Completed

Conditions: Chronic Low Back Pain

Interventions: Drug: ABT-712
Drug: Placebo

First Posted Date: 2008-09-30

Last Posted Date: 2014-02-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 287

Registration Number: NCT00763321

Locations: 🇺🇸
Site Reference ID/Investigator# 10041, Pasadena, Maryland, United States
🇺🇸
Site Reference ID/Investigator# 10062, Biloxi, Mississippi, United States
🇺🇸
Site Reference ID/Investigator# 10066, Florissant, Missouri, United States

and more 28 locations

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

Phase 3

Completed

Conditions: Chronic Low Back Pain

Interventions: Drug: Placebo
Drug: ABT-712

First Posted Date: 2008-09-29

Last Posted Date: 2014-02-07

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 308

Registration Number: NCT00761150

Locations: 🇺🇸
Site Reference ID/Investigator# 10152, Clearwater, Florida, United States
🇺🇸
Site Reference ID/Investigator# 10147, Pembroke Pines, Florida, United States
🇺🇸
Site Reference ID/Investigator# 15821, Chicago, Illinois, United States

and more 29 locations

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Phase 2

Completed

Conditions: Hematologic Cancer

Interventions: Biological: elotuzumab
Drug: lenalidomide
Drug: dexamethasone oral
Drug: dexamethasone injection

First Posted Date: 2008-08-27

Last Posted Date: 2018-01-10

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 101

Registration Number: NCT00742560

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: ABT-869

First Posted Date: 2008-08-12

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 34

Registration Number: NCT00733187

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

Phase 2

Completed

Conditions: HCV Infection

Interventions: Procedure: Blood sample collection only
Drug: ABT-333

First Posted Date: 2008-08-01

Last Posted Date: 2015-01-08

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 35

Registration Number: NCT00726882

Locations: 🇺🇸
Site Reference ID/Investigator# 17672, Los Angeles, California, United States
🇺🇸
Site Reference ID/Investigator# 17665, Anaheim, California, United States
🇺🇸
Site Reference ID/Investigator# 10381, Orlando, Florida, United States

and more 4 locations

A Phase 1 Study of ABT-869 in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: ABT-869

First Posted Date: 2008-07-18

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 18

Registration Number: NCT00718380

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: ABT-869
Drug: Placebo for ABT-869
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2008-07-16

Last Posted Date: 2013-04-29

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 145

Registration Number: NCT00716534

Locations: 🇺🇸
Site Reference ID/Investigator# 13101, Philadelphia, Pennsylvania, United States
🇺🇸
Site Reference ID/Investigator# 24122, Philadelphia, Pennsylvania, United States
🇧🇷
Site Reference ID/Investigator# 22684, Santo Andre, Brazil

and more 34 locations

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Biological: ABT-874
Biological: etanercept
Drug: placebo

First Posted Date: 2008-07-04

Last Posted Date: 2013-01-18

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 350

Registration Number: NCT00710580

Locations: 🇺🇸
Site Reference ID/Investigator# 9981, Dallas, Texas, United States
🇺🇸
Site Reference ID/Investigator# 10502, Little Rock, Arkansas, United States
🇺🇸
Site Reference ID/Investigator# 10762, Atlanta, Georgia, United States

and more 39 locations

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Advanced Colorectal Cancer
Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum

Interventions: Drug: bevacizumab
Drug: ABT-869
Drug: oxaliplatin
Drug: folinic acid
Drug: fluorouracil

First Posted Date: 2008-07-01

Last Posted Date: 2013-05-15

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 159

Registration Number: NCT00707889

Locations: 🇺🇸
Site Reference ID/Investigator# 11341, Chapel Hill, North Carolina, United States
🇺🇸
Site Reference ID/Investigator# 20801, Philadelphia, Pennsylvania, United States
🇦🇺
Site Reference ID/Investigator# 18581, Bedford Park, Australia

and more 43 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy